stockrowDENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
Follow XRAY
Alert me
DENTSPLY SIRONA Inc. (XRAY) Return on invested capital
DENTSPLY SIRONA Inc.'s return on invested capital over the twelve months to 30 September 2026 was −1.09%, up 7.6 percentage points from fiscal 2025 (−8.71%). Over the past ten years it has ranged from −16.9% (fiscal 2024) to 7.34% (fiscal 2015); the current reading is higher than 45% of that period. That is below the Medical Instruments & Supplies industry median of 0.13% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −8.71% | 8.16 |
| FY2024 | −16.9% | (15.75) |
| FY2023 | −1.12% | 9.99 |
| FY2022 | −11.1% | (16.89) |
| FY2021 | 5.78% | 5.81 |
| FY2020 | −0.03% | (3.63) |
| FY2019 | 3.60% | 12.97 |
| FY2018 | −9.37% | 2.96 |
| FY2017 | −12.3% | (15.40) |
| FY2016 | 3.07% | (4.27) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | 22.1% |
| STVN Stevanato Group S.p.A. compare | 6.71% |
| ATRC AtriCure, Inc. compare | 2.61% |
| WRBY Warby Parker Inc. compare | 0.83% |
| STAA STAAR Surgical Company compare | 0.26% |
| XRAY DENTSPLY SIRONA Inc. | −1.09% |
| AZTA Azenta, Inc. compare | −9.27% |
| PLSE Pulse Biosciences, Inc compare | −37.0% |
| KMTS Kestra Medical Technologies, Ltd. compare | −93.5% |
| Medical Instruments & Supplies industry median | 0.13% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on XRAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement